Janus kinase inhibitors for the treatment of atopic dermatitis: Real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures.
Reguiai Z, Becherel PA, Fougerousse AC, Chaby G, Perrot JL, Begon E, Jacobzone-Lévêque C, Boulard C, Badaoui A, Poreaux C, David L, Quiles-Tsimaratos N, Lons-Danic D, Fite C, Liegeon AL, Patchinsky A, Parier J, Garcia C, Estève E, Mohty R, Mery-Bossard L, Maccari F.
Reguiai Z, et al. Among authors: fite c.
J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1307-e1309. doi: 10.1111/jdv.19302. Epub 2023 Jul 14.
J Eur Acad Dermatol Venereol. 2023.
PMID: 37415328
No abstract available.